Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.

Abstract

BACKGROUND:

Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes. Across the SURPASS-1 to -5 clinical studies, tirzepatide 5, 10 and 15 mg demonstrated significant improvements in glycated haemoglobin A1c (HbA1c) (- 1.9 to - 2.6%), body weight (- 6.6 to - 13.9%) and systolic blood pressure (SBP) (- 2.8 to - 12.6 mmHg) at the end of study treatment.

METHODS:

Post-hoc mediation analyses were conducted to evaluate weight-loss dependent and weight-loss independent effects of tirzepatide on SBP reductions across the 5 SURPASS studies. The safety population (all randomized patients who took at least 1 dose of study drug) of each study was analyzed. Additional analyses were conducted at individual study level or pooled across 5 SURPASS trials.

RESULTS:

The difference in mean SBP change from baseline at 40 weeks (total effect) between the tirzepatide and comparator groups was - 1.3 to - 5.1 mmHg (tirzepatide 5 mg), - 1.7 to - 6.5 mmHg (tirzepatide 10 mg) and - 3.1 to - 11.5 mmHg (tirzepatide 15 mg). These SBP reductions were primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. In the SURPASS-4 study, which enrolled patients with established cardiovascular disease, weight-loss independent effects explained 33% to 57% of difference in SBP change between tirzepatide and insulin glargine groups. In a pooled analysis of the SURPASS-1 to -5 studies, there was a significant (p < 0.001) but weak correlation (r = 0.18 to 0.22) between change in body weight and SBP. Reductions in SBP with tirzepatide were not dependent on concomitant antihypertensive medications at baseline as similar reductions were observed whether participants were receiving them or not (interaction p = 0.77). The largest SBP reductions were observed in the highest baseline category (> 140 mmHg), while those in the first quartile of baseline SBP category (< 122 mmHg) observed no further decrease in SBP.

CONCLUSIONS:

Tirzepatide-induced SBP reduction was primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. SBP reduction was not dependent on antihypertensive medication use but dependent on baseline SBP value, alleviating theoretical concerns of hypotension.

• Authors: Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, Xuewei Cui, Ciara O'Neill, Laura Fernández Landó, Hiren Patel
• Journal: Cardiovascular diabetology (Cardiovasc Diabetol) Vol. 22 Issue 1 Pg. 66 (03 24 2023) ISSN: 1475-2840 [Electronic] England
• PMID: 36964557 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2023. The Author(s).

Chemical References

• Antihypertensive Agents
• tirzepatide
• Gastric Inhibitory Polypeptide
• Hypoglycemic Agents
• Glucagon-Like Peptide-1 Receptor

Topics

• Humans
• Diabetes Mellitus, Type 2 (diagnosis, drug therapy)
• Blood Pressure
• Antihypertensive Agents (adverse effects)
• Gastric Inhibitory Polypeptide (therapeutic use)
• Hypotension (chemically induced, complications, drug therapy)
• Body Weight
• Weight Loss
• Hypoglycemic Agents (adverse effects)
• Glucagon-Like Peptide-1 Receptor (agonists)